We are monitoring the impact of COVID-19 & Recession alarm on APAC Clinical Trials Market Get in touch with us for detailed analysis Know More
Share on

Asia Pacific Clinical Trials Market Analysis – Segmented By Phase, Design, Indications, By Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends, & Forecast | 2022 to 2027

Published: January, 2022
ID: 1573
Pages: 135

The size of the Asia Pacific Clinical Trials market has been estimated at USD 4.11 Billion in 2022 and is projected to reach USD 6.29 Billion by 2027 at a CAGR of 8.9% during the forecast period.

Clinical Trial is a part of clinical research that follows a regulated protocol. Clinical Trials are primarily performed to get data on safety and efficacy of the new developed drug. Clinical Trials data is mandatory for further approval of the drug and to bring it into the market. They allow the drug to be tested for safety by different ethnic population. Due to the higher medical needs and increasing disease prevalence, developing countries are becoming a hub for Clinical Trials implementation.

The Indian clinical trials market is growing at a healthy rate. The Indian biopharmaceutical industry is one of the leading industry in the world. Many companies are conducting a clinical trial for COVID – 19 in collaboration with research centers. The vaccine is the only remedy for the viral pandemic the trials are put on the fast track to develop a vaccine as first as possible. India has a great population and geographical diversity which is important for a clinical trial. This is boosting the growth of the market in India. Glenmark Pharmaceutical has initiated phase III of clinical trials in India using Favipiravir. Even BCG is also used to develop a vaccine for COVID -19.

The Chinese clinical trial market is showcasing promising growth. The government is investing in R&D in the pharma sector, which is driving market growth. China till now has approved three COVID- 19 vaccines in the second phase of a clinical trial. China has a great infrastructure for clinical trial and a large patient population which are driving the market growth.

The Japanese government has allowed the use of foreign clinical trial data. The contract research organization has started to invest in the clinical trial market, which is boosting the market growth. Japan is expected to launch clinical trials for COVID- 19 in July.

The Australian government is investing on clinical trials to increase the research and development in the country. This is boosting the market in the country. Clinical trials are going on two vaccines for COVID- 19.

There are about 184 institutions for a clinical trial in South Korea. The Novotech is doing clinical trials for Komipharma for COVID – 19 in South Korea. 

MARKET DRIVERS

The market for Clinical Trials is mainly driven due to advancement in technology and increasing demand of innovative solutions in healthcare, the cost competitiveness factor where the cost involved in performing a Clinical Trials in emerging nations is very less compared to Western nations and lenient regulatory matters.

MARKET RESTRAINTS

The Asia Pacific clinical trials market growth will be constrained due to emerging shortage of clinical resources such as lack of naïve disease population, well trained labor, and sound medical infrastructure which are delaying the process to initiate trials.

This report on APAC Clinical Trails Market has been segmented into the following categories:

  • By Phase – Phase I, Phase II, Phase III
  • By Design - Interventional trials, Observational trials, Expanded Access trials
  • By Indications – Autoimmune, Blood disorders, Cancer, Circulatory, CNS, Congenital, CVS, Dermatology, Ear, Gastrointestinal, Genitourinary, Infections, Mental disorders, Metabolic, Musculoskeletal, Nose & Ophthalmology  
  • By Country - India, China, Japan, South Korea,  Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC

Geographically, the Clinical Trials market in the Asia-Pacific region is projected to grow at the highest CAGR in the Global Clinical Trials Market, which is greatly due to initiatives from the government and contributions from academic laboratories, which helped augment growth. Due to the large population in this region, it helps in faster enrollment of the patients, and retention of the participants in the trials on the higher side; thereby helping the companies to conduct the trials on a timely basis.

Few of the major companies leading the APAC Clinical Trials Market are Chiltern, Omnicare, PPD, Parexel, Kendle, Quintiles, ICON Plc and Charles River.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                             4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Phases                          

                                5.1.1 Introduction           

                                5.1.2 Phase I      

                                5.1.3 Phase II    

                                5.1.4 Phase III   

                                5.1.5  Y-o-Y Growth Analysis, By Phases                

                                5.1.6  Market Attractiveness Analysis, By Phases              

                                5.1.7  Market Share Analysis, By Phases                

                5.2 Design                          

                                5.2.1 Introduction           

                                5.2.2 Interventional trials             

                                5.2.3 Observational trials             

                                5.2.4 Expanded Access trials       

                                5.2.5  Y-o-Y Growth Analysis, By Design 

                                5.2.6  Market Attractiveness Analysis, By Design               

                                5.2.7  Market Share Analysis, By Design

                5.3 Indications                  

                                5.3.1 Introduction           

                                5.3.2 Autoimmune         

                                5.3.3 Blood disorders     

                                5.3.4 Cancer      

                                5.3.5 Circulatory               

                                5.3.6 CNS            

                                5.3.7 Congenital               

                                5.3.8 CVS            

                                5.3.9 Dermatology          

                                5.3.10 Ear            

                                5.3.11 Gastrointestinal  

                                5.3.12 Genitourinary      

                                5.3.13 Infections              

                                5.3.14 Mental disorders

                                5.3.15 Metabolic              

                                5.3.16 Musculoskeletal 

                                5.3.17 Nose       

                                5.3.18 Ophthalmology   

                                5.3.19  Y-o-Y Growth Analysis, By Indications      

                                5.3.20  Market Attractiveness Analysis, By Indications    

                                5.3.21  Market Share Analysis, By Indications      

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Phase

                                                6.1.3.3 By Design

                                                6.1.3.4 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Phase

                                                6.1.4.3 By Design

                                                6.1.4.4 By Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Phase

                                                6.1.5.3 By Design

                                                6.1.5.4 By Indication

                6.2 China                             

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea                               

                6.6 Australia                      

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Chiltern                        

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Omnicare                    

                8.3 PPD                

                8.4 Parexel                         

                8.5 Kendle                          

                8.6 Quintles                       

                8.7 ICON Plc                       

                8.8 Charles River                              

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Asia-Pacific Clinical Trial Market By Phase, From 2022 - 2027 ( USD Billion )
  2. Asia-Pacific Phase I Market By Region, From 2022 - 2027 ( USD Billion )
  3. Asia-Pacific Phase II Market By Region, From 2022 - 2027 ( USD Billion )
  4. Asia-Pacific Phase III Market By Region, From 2022 - 2027 ( USD Billion )
  5. Asia-Pacific Clinical Trial Market By Design, From 2022 - 2027 ( USD Billion )
  6. Asia-Pacific Interventional trials Market By Region, From 2022 - 2027 ( USD Billion )
  7. Asia-Pacific Observational trials Market By Region, From 2022 - 2027 ( USD Billion )
  8. Asia-Pacific Expanded Access trials Market By Region, From 2022 - 2027 ( USD Billion )
  9. Asia-Pacific Clinical Trial Market By Indications, From 2022 - 2027 ( USD Billion )
  10. Asia-Pacific Autoimmune Market By Region, From 2022 - 2027 ( USD Billion )
  11. Asia-Pacific Blood disorders Market By Region, From 2022 - 2027 ( USD Billion )
  12. Asia-Pacific Cancer Market By Region, From 2022 - 2027 ( USD Billion )
  13. Asia-Pacific Circulatory Market By Region, From 2022 - 2027 ( USD Billion )
  14. Asia-Pacific CNS Market By Region, From 2022 - 2027 ( USD Billion )
  15. Asia-Pacific Congenital Market By Region, From 2022 - 2027 ( USD Billion )
  16. Asia-Pacific CVS Market By Region, From 2022 - 2027 ( USD Billion )
  17. Asia-Pacific Dermatology Market By Region, From 2022 - 2027 ( USD Billion )
  18. Asia-Pacific Ear Market By Region, From 2022 - 2027 ( USD Billion )
  19. Asia-Pacific Gastrointestinal Market By Region, From 2022 - 2027 ( USD Billion )
  20. Asia-Pacific Genitourinary Market By Region, From 2022 - 2027 ( USD Billion )
  21. Asia-Pacific Infections Market By Region, From 2022 - 2027 ( USD Billion )
  22. Asia-Pacific Mental disorders Market By Region, From 2022 - 2027 ( USD Billion )
  23. Asia-Pacific Metabolic Market By Region, From 2022 - 2027 ( USD Billion )
  24. Asia-Pacific Musculoskeletal Market By Region, From 2022 - 2027 ( USD Billion )
  25. Asia-Pacific Nose Market By Region, From 2022 - 2027 ( USD Billion )
  26. Asia-Pacific Ophthalmology Market By Region, From 2022 - 2027 ( USD Billion )
  27. Japan Clinical Trial Market By Phase, From 2022 - 2027 ( USD Billion )
  28. Japan Clinical Trial Market By Design, From 2022 - 2027 ( USD Billion )
  29. Japan Clinical Trial Market By Indications, From 2022 - 2027 ( USD Billion )
  30. China Clinical Trial Market By Phase, From 2022 - 2027 ( USD Billion )
  31. China Clinical Trial Market By Design, From 2022 - 2027 ( USD Billion )
  32. China Clinical Trial Market By Indications, From 2022 - 2027 ( USD Billion )
  33. India Clinical Trial Market By Phase, From 2022 - 2027 ( USD Billion )
  34. India Clinical Trial Market By Design, From 2022 - 2027 ( USD Billion )
  35. India Clinical Trial Market By Indications, From 2022 - 2027 ( USD Billion )
  36. Australia Clinical Trial Market By Phase, From 2022 - 2027 ( USD Billion )
  37. Australia Clinical Trial Market By Design, From 2022 - 2027 ( USD Billion )
  38. Australia Clinical Trial Market By Indications, From 2022 - 2027 ( USD Billion )
  39. South Korea Clinical Trial Market By Phase, From 2022 - 2027 ( USD Billion )
  40. South Korea Clinical Trial Market By Design, From 2022 - 2027 ( USD Billion )
  41. South Korea Clinical Trial Market By Indications, From 2022 - 2027 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample